Hartoun Hartounian
Corporate Officer/Principal bei San Diego Tech Coast Angels
Profil
Hartoun Hartounian was the founder of Protagenic Therapeutics, Inc. (founded in 1994) where he held the title of Director.
He is currently a Member at San Diego Tech Coast Angels.
Hartounian's former positions included President, Chief Executive Officer & Director at Vyteris, Inc. (2011), Director-Process Development at Monsanto Co. (1998-2001), Director at Protagenic Therapeutics, Inc. (2006-2010), and President, Chief Operating Officer & Director at MicroIslet, Inc. (2006).
He was also an Adjunct Assistant Professor at Drexel University.
Hartounian received a graduate degree from the University of California, Los Angeles and a doctorate from the University of Delaware.
Aktive Positionen von Hartoun Hartounian
| Unternehmen | Position | Beginn |
|---|---|---|
| San Diego Tech Coast Angels | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Hartoun Hartounian
| Unternehmen | Position | Ende |
|---|---|---|
Vyteris, Inc.
 Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | Präsident | 09.08.2011 |
MicroIslet, Inc.
 MicroIslet, Inc. Miscellaneous Commercial ServicesCommercial Services MicroIslet, Inc. operates as a biotechnology company, which researches, develops, and commercializes patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. The company was founded on August 21, 1998 and is headquartered in San Diego, CA. | Präsident | 17.02.2006 |
| MONSANTO | Corporate Officer/Principal | 01.01.2001 |
| PROTAGENIC THERAPEUTICS, INC. | Gründer | - |
Protagenic Therapeutics, Inc. /Old/
 Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Direktor/Vorstandsmitglied | - |
Ausbildung von Hartoun Hartounian
| University of California, Los Angeles | Graduate Degree |
| University of Delaware | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PROTAGENIC THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Monsanto Co.
 Monsanto Co. Wholesale DistributorsDistribution Services Monsanto Co. engages in the provision of agricultural products to farmers. It provides other seed companies with genetic material and biotechnology traits for their seed brands. The company was founded by John F. Queeny in 1901 and is headquartered in St. Louis, MO. | Distribution Services |
Vyteris, Inc.
Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | Health Technology |
Protagenic Therapeutics, Inc. /Old/
Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Health Technology |
MicroIslet, Inc.
MicroIslet, Inc. Miscellaneous Commercial ServicesCommercial Services MicroIslet, Inc. operates as a biotechnology company, which researches, develops, and commercializes patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. The company was founded on August 21, 1998 and is headquartered in San Diego, CA. | Commercial Services |
| San Diego Tech Coast Angels |